Stock Price Forecast The 8 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 27.00, with a high estimate of 35.00 and a low estimate of 17.00. The median estimate represents a +129.01% increase from the last price of 11.79.
Why is Cara stock dropping?
The big drop came after the drugmaker announced results from a phase 2 clinical study evaluating Oral Korsuva in treating chronic kidney disease (CKD) patients with moderate to severe pruritis (itching).Dec 3, 2019
Is RXT a buy?
Out of 7 analysts, 1 (14.29%) are recommending RXT as a Strong Buy, 3 (42.86%) are recommending RXT as a Buy, 3 (42.86%) are recommending RXT as a Hold, 0 (0%) are recommending RXT as a Sell, and 0 (0%) are recommending RXT as a Strong Sell. What is RXT's earnings growth forecast for 2022-2023?
What does Cara Therapeutics do?
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).
Will Cara Therapeutics go up?
The 8 analysts offering 12-month price forecasts for Cara Therapeutics Inc have a median target of 27.00, with a high estimate of 35.00 and a low estimate of 17.00. The median estimate represents a +129.01% increase from the last price of 11.79.
Who owns Cara Therapeutics?
Stockholder Stake Shares owned
------------------------------------ ----- ------------
The Vanguard Group, Inc. 5.49% 2,933,374
Farallon Capital Management LLC 3.74% 2,000,000
Disciplined Growth Investors, Inc 3.12% 1,669,089
SSgA Funds Management, Inc. 2.81% 1,504,166
Will Cara Therapeutics get FDA approval?
FDA Approval of KORSUVA It is the first and only approved treatment for pruritus associated with CKD disease and hemodialysis. Cara Therapeutics will bring the drug to the U.S. market through a 60/40 partnership with Vifor Pharma. The launch will occur during Q1-2022.
Is Cara a good stock to buy?
Cara Therapeutics has received a consensus rating of Buy.
Who is Sorrento Therapeutics owned by?
A proprietary name review by the FDA is planned. Seprehvir® is a registered trademark of Virttu Biologics Limited, a wholly owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc. (1) Decisions Resources Group.Dec 6, 2021